期刊文献+

健脾清肠汤对溃疡性结肠炎肠黏膜屏障及免疫功能的影响 被引量:4

Study on the Effect of Decoction for Invigorating Spleen Bowel Intestinal Mucous Colitis Barrier and Immune Function of Ulcer
原文传递
导出
摘要 目的探讨健脾清肠汤对溃疡性结肠炎肠黏膜屏障及免疫功能的影响。方法收集我院接诊的100例溃疡性结肠炎患者资料,将患者随机分为观察组和对照组,各50例。观察组患者采用健脾清肠汤治疗,对照组患者采用柳氮磺胺嘧啶及诺氟沙星胶囊治疗。比较两组患者肠黏膜屏障情况与治疗前后的免疫球蛋白G(Ig G)与补体C3。结果治疗后,观察组与对照组患者的肠黏膜屏障未痊愈率分别为16.0%、38.0%;观察组患者的Ig G与补体C3均高于对照组,差异均有统计学意义(均P<0.05)。结论健脾清肠汤治疗溃疡性结肠炎能有效促进肠黏膜屏障痊愈,并能提高患者的免疫功能。 Objective To investigate the influence of the spleen soup ulcerative colitis bowel intestinal barrier and immune function.Methods We col ection 100 cases of ulcerative colitis patients in our hospital admissions,were randomly divided into observation group and control group,each of 50 cases.The observation group with spleen Qingchang soup treatment,the control group using sulfasalazine and Norfloxacin Capsules treatment.Before and after treatment were compared between the two groups of barrier and intestinal mucosa in patients with immunoglobulin G(IgG)and complement C3.Results After treatment,the observation group and the control group of patients without intestinal mucosal barrier recovery rate were 16.0%,38.0%;observation of IgG and complement C3 group patients were higher than those of the control group,the difference was statistical y significant(P〈0.05).Conclusion Spleen bowel Decoction in the treatment of ulcerative colitis can effectively promote the intestinal mucosal barrier recovery, and can improve the immune function of patients.
出处 《中国药物经济学》 2015年第3期95-97,共3页 China Journal of Pharmaceutical Economics
关键词 健脾清肠汤 溃疡性结肠炎 肠黏膜屏障 Spleen and bowel soup Ulcerative colitis Intestinal mucosal barrier
  • 相关文献

参考文献6

二级参考文献18

  • 1欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495. 被引量:751
  • 2Beattie RM,Nicholls SW,Domizio P,et al.Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis[J].J Pediatr Gastroenterol Nutr,1996,22:373-379.
  • 3Powell-Tuck J,Bown RL,Lennard-Jones JE.A comparison of oral prednisolone given as single or multiple daily doses or active proctocolitis[J].Scand J Gastroenterol,1978,13:833-837.
  • 4Lichtiger S,Present DH.Preliminary report:cyclosporine in treatment of severe active ulcerative colitis[J].Lancet,1990,336:16-19.
  • 5Seo M,Okada M,Yao T,et al.An index of disease activity in patients with ulcerative colitis[J].Am J Gastroenterol,1992,87:971-976.
  • 6Walmsley RS,Ayres RC,Pounder RE,et al.A simple clinical colitis activity index[J].Gut,1998,43:29-32.
  • 7Schroeder KW,Tremaine WJ,Ilstrup DM.Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis:a randomized study[J].N Engl J Med,1987,317:1625-1629.
  • 8Turner D,Otley AR,Mack D,et al.Development and evaluation of a Pediatric Ulcerative Colitis Activity Index(PUCAI):a prospective multicenter study[J].Gastroenterology,2007,133:423-432.
  • 9Azzolini F,Pagnini C,Camellini L,et al.Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis[J].Dig Dis Sci,2005,50:246-251.
  • 10Rachmilewitz D.Coated mesalazine(5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis:a randomized trial[J].BMJ,1989,298:82-86.

共引文献37

同被引文献40

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部